Journal
SEMINARS IN LIVER DISEASE
Volume 37, Issue 2, Pages 109-118Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0037-1601349
Keywords
hepatitis C; hepatocellular carcinoma; direct antiviral agents; incidence; recurrence
Categories
Funding
- Instituto de Salud Carlos III [PI15/00145, PI15/00151, PI14/00962]
- AECC [PI044031]
- WCR (AICR) [16-0026]
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement [2014 SGR 605, 2014 SGR 233]
- Spanish Health Ministry (Plan Estrategico Nacional contra la Hepatitis C)
Ask authors/readers for more resources
The availability of new direct antiviral agents to safely and effectively treat the hepatitis C virus represents a major advancement in the field of liver disease. Most patients achieve complete viral eradication sustained over time. In addition, the administration of these new agents is safe and does not require limitations when liver function is impaired. Some now expect the hepatitis C virus to be completely eradicated in a few years. However, not all data are positive. In April 2016, we published a cohort study suggesting that viral eradication with the new agents could be associated in time with the emergence of recurrent cancer sites in patients previously treated for hepatocellular carcinoma. In this review, we update our report and summarize the data provided in recent publications. We also speculate about themechanisms for cancer emergence and stress the need for further studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available